Actively Recruiting

Age: 18Years +
All Genders
NCT04405583

The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients

Led by Occlutech International AB · Updated on 2026-01-29

150

Participants Needed

36

Research Sites

361 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to monitor the safety and efficacy of Occlutech AFR device in patients with Heart Failure.

CONDITIONS

Official Title

The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent
  • Age 18 years or older
  • Chronic symptomatic heart failure with NYHA class 2 or higher
  • Left atrial pressure greater than right atrial pressure with a gradient of at least 5 mmHg
  • Left ventricular ejection fraction of 15% or higher; if above 40%, elevated NT-pro-BNP levels adjusted for body mass index
  • Stable guideline-directed heart failure treatment for at least 1 month before consent
Not Eligible

You will not qualify if you...

  • Life expectancy less than 1 year or advanced heart failure (ACC/AHA Stage D) or listed for heart transplant
  • Severe right ventricular dysfunction or dilatation or severe pulmonary hypertension
  • Echocardiographic evidence of intra-cardiac mass, thrombus, or vegetation
  • Uncontrolled hypertension with systolic blood pressure above 160 mmHg or diastolic above 100 mmHg despite therapy
  • Uncontrolled atrial fibrillation with resting heart rate over 110 bpm despite therapy
  • History of specific cardiomyopathies or pericardial disease
  • Congenital heart defect interfering with device placement
  • Previous atrial septal defect or patent foramen ovale closure interfering with device placement
  • Current atrial septal defect or anatomical anomalies preventing device implantation
  • Significant valvular heart disease (regurgitation grade 3 or higher, severe stenosis)
  • Prior diagnosis of primary pulmonary hypertension
  • Severe COPD requiring steroids or oxygen
  • Stroke, TIA, DVT, pulmonary embolism within 6 months or prior stroke with neurologic deficit
  • Recent myocardial infarction or coronary intervention within 2 months
  • ICD or right-sided pacemaker placed within 2 months
  • Significant coagulation disorders
  • Sepsis or acute infection requiring antibiotics within 2 months
  • Chronic kidney disease requiring dialysis
  • Allergy to device materials or related therapies if not manageable
  • Participation in another interfering clinical trial
  • Other significant comorbidities making participation unsuitable

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 36 locations

1

CHU Besançon

Besançon, France

Actively Recruiting

2

CHU Bourdeaux

Bourdeaux, France

Actively Recruiting

3

CHU Lyon

Lyon, France

Actively Recruiting

4

CHU Montpellier

Montpellier, France

Actively Recruiting

5

Centre Hospitalier Universitaire Rangueil

Toulouse, France

Not Yet Recruiting

6

Knappschaftskrankenhaus Bottrop GmbH

Bottrop, Germany

Not Yet Recruiting

7

Clinic Coburg

Coburg, Germany

Actively Recruiting

8

University Clinic

Cologne, Germany

Actively Recruiting

9

Helios Clinic Erfurt

Erfurt, Germany

Active, Not Recruiting

10

Cardiologicum Hamburg

Hamburg, Germany

Terminated

11

WKK Heide

Heide, Germany

Actively Recruiting

12

University Clinic Jena

Jena, Germany

Actively Recruiting

13

Hospital Osnabrueck

Osnabrück, Germany

Actively Recruiting

14

Elbe Clinic Stade

Stade, Germany

Actively Recruiting

15

University Clinic Tübingen

Tübingen, Germany

Active, Not Recruiting

16

Hippokration Hospital Athens

Athens, Greece

Actively Recruiting

17

Mitera Hospital Athens

Athens, Greece

Not Yet Recruiting

18

Onassis Cardiac Surgery Center

Athens, Greece

Not Yet Recruiting

19

European Interbalkan Medical Center

Thessaloniki, Greece

Actively Recruiting

20

Hippokration Hospital of Thessaloniki

Thessaloniki, Greece

Actively Recruiting

21

Careggi University Hospital

Florence, Italy

Not Yet Recruiting

22

Centro Cardiologico Monzino

Milan, Italy

Actively Recruiting

23

Hospital de Santa Cruz

Carnaxide, Portugal

Not Yet Recruiting

24

Hospital de Santa Marta

Lisbon, Portugal

Not Yet Recruiting

25

Dedinje Cardiovascular Institute

Dedinje, Serbia

Not Yet Recruiting

26

Rabta Hospital

Tunis, Tunisia

Actively Recruiting

27

The Military Hospital of Tunis

Tunis, Tunisia

Actively Recruiting

28

Ankara Etlik Şehir Hastanesi

Ankara, Turkey (Türkiye)

Actively Recruiting

29

Güven Hospital

Ankara, Turkey (Türkiye)

Actively Recruiting

30

Hacettepe Üniversitesi Tip Fakültesi

Ankara, Turkey (Türkiye)

Actively Recruiting

31

Firat University Hospital

Elâzığ, Turkey (Türkiye)

Actively Recruiting

32

Binali Yildirim University Mengücek Gazi Training and Resear

Erzincan, Turkey (Türkiye)

Actively Recruiting

33

Bezmialem Uni. Hospital

Fatih, Turkey (Türkiye)

Actively Recruiting

34

İzmir City Hospital

Izmir, Turkey (Türkiye)

Actively Recruiting

35

Kocaeli Üniversitesi Araştirma Ve Uygulama Hastanesi

Kocaeli, Turkey (Türkiye)

Actively Recruiting

36

Namik Kemal University Hospital

Tekirdağ, Turkey (Türkiye)

Actively Recruiting

Loading map...

Research Team

G

Gönül Sonmez Utkun

CONTACT

S

Sankoung Minte

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients | DecenTrialz